Crinetics Pharmaceuticals (CRNX) Stock
Drug developer in trials for rare endocrine disorders. Here's the price, business snapshot, and what's worth knowing about Crinetics Pharmaceuticals in June 2026.
Crinetics Pharmaceuticals (CRNX) is a clinical‑stage biopharmaceutical company focused on developing therapies for rare endocrine disorders. With a market capitalisation around $4.04 billion, the company’s value is driven largely by progress through clinical trials, regulatory milestones and potential partnerships or licensing deals. Investors should note that clinical‑stage companies often have limited to no product revenue and rely on funding rounds or collaborations to finance development and commercialisation. Key considerations include the timing and outcomes of pivotal study readouts, the competitive landscape for specialised endocrine therapies, manufacturing and regulatory risk, and the potential for share dilution if additional capital is required. While upside can be material if trials succeed and approvals follow, the path is binary and outcomes can be volatile. This summary is educational only and not personalised investment advice; consider your risk tolerance and consult a financial adviser before making decisions.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Crinetics Pharmaceuticals' stock, expecting its price to rise significantly.
Financial Health
Crinetics Pharmaceuticals is generating strong revenue and cash flow, indicating good financial performance.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring CRNX
Rare Kidney Disease Treatments | A Market Overview
The FDA's expanded approval of Travere's FILSPARI validates the growing market for rare nephrology treatments. This milestone creates positive momentum for biopharma companies developing innovative therapies for underserved kidney conditions.
Published: 14 April 2026
Explore BasketBiotech Buyout Wave Targets Obesity Market 2025
Pfizer's bid for obesity drug maker Metsera has turned into a legal battle after a counteroffer from Novo Nordisk, highlighting the fierce competition in the weight-loss market. This intense M&A activity signals that other biotech companies with promising obesity treatments could become the next valuable acquisition targets.
Published: 1 November 2025
Explore BasketWeight-Loss Drug Shakeup: What's Next for Biotechs?
Following former President Trump's pledge to slash prices for popular weight-loss drugs, uncertainty has hit major pharmaceutical stocks. This theme identifies competitor firms and biotechs that could gain an edge as the pricing landscape for metabolic drugs shifts.
Published: 18 October 2025
Explore BasketMASH Stocks: Could Roche's Deal Spark More M&A?
Roche's $3.5 billion acquisition of 89bio for its liver disease drug highlights the growing MASH treatment market. This deal creates a potential tailwind for other biopharmaceutical companies developing therapies for liver and metabolic conditions.
Published: 21 September 2025
Explore BasketObesity Treatment (Pharma Giants vs Biotech Firms)
Novo Nordisk's major restructuring, driven by intense competition from Eli Lilly, highlights the high-stakes battle in the weight-loss drug market. This theme focuses on other pharmaceutical companies that could benefit from this rivalry, either as innovators with next-generation treatments or as potential acquisition targets.
Published: 10 September 2025
Explore BasketWhy You’ll Want to Watch This Stock
Pipeline catalysts
Clinical trial readouts and regulatory milestones can materially move the share price, though outcomes are binary and uncertain.
Endocrine focus
Targets rare hormonal disorders where successful drugs can command premium pricing, but niche markets and commercial execution carry risk.
Financing and risk
Ongoing development may require additional capital, creating dilution risk; keep in mind clinical, regulatory and competitive uncertainties.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
